在小鼠动脉样硬化中,脂质过氧化和血小板激活
1Center for Experimental Therapeutics, Department of Pharmacology, University of Pennsylvania, Philadelphia, USA.
Circulation
|October 17, 2001
概括
脂质过氧化和血小板激活在动脉样硬化中同时发生. 将抗氧化剂与血小板抑制剂结合起来,可能为预防人类动脉样硬化进展提供了一个新的策略.
科学领域:
- 心血管研究研究心血管研究
- 动脉样硬化病原体的产生
- 氧化压力生物学 氧化压力生物学
背景情况:
- 脂质过氧化和血小板激活与动脉样硬化有关.
- 这些因素在动脉样硬化中的体内相互作用仍然不清楚.
研究的目的:
- 为了研究脂质过氧化和动脉样硬化中的血小板激活之间的相互作用.
- 评估针对这些途径的治疗潜力.
主要方法:
- 使用高脂肪饮食中的LDL受体缺乏 (LDLR(-/-)) 小鼠诱导动脉样硬化.
- 作为标记物,测量了8,12-iso-isoprostane F(2alpha) -VI和2,3-dinor-thromboxane B(2) 的尿液水平.
- 单独或组合使用维生素E (抗氧化剂) 和印梅他辛 (血小板抑制剂).
主要成果:
- 高脂肪饮食诱导了动脉样硬化,增加了脂质过氧化和血小板激活的标志物.
- 维生素E降低了动脉样硬化65%,但没有影响脂质水平或血红素B.
- 组合疗法显著降低了两种标志物和动脉样硬化症的80%,也降低了炎症标志物.
结论:
- 在体内脂质过氧化和血小板激活是不同的,但在小鼠动脉样硬化中共存的过程.
- 氧化应激和血小板激活是动脉生成中单独的治疗点.
- 结合抗氧化剂和抗血小板疗法显示,有望预防人类动脉样硬化进展.
相关概念视频
Inflammation
Overview
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...


